ERBB2 and breast cancer: Trastuzumab is a recombinant immunoglobulin G1 (IgG1) monoclonal antibody that binds HER2 and is approved for the treatment of metastatic breast cancer, early breast cancer, and metastatic gastric cancer (1,2).